Fate Therapeutics (NASDAQ: FATE) holder to sell 10,589 shares of stock

Rhea-AI Filing Summary

Fate Therapeutics has a Form 144 notice indicating a shareholder plans to sell 10,589 shares of common stock through Fidelity Brokerage Services on NASDAQ, with an aggregate market value of 11,275.17. These shares were acquired on 01/08/2026 via restricted stock vesting as compensation from the issuer. Shares of common stock outstanding were 115,352,289 at the time referenced, which serves as a baseline figure.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	10589	11275.17	115352289	01/09/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	01/08/2026	Restricted Stock Vesting	Issuer			10589	01/08/2026	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filing for FATE disclose?

It discloses that a Fate Therapeutics shareholder plans to sell 10,589 shares of common stock on NASDAQ through Fidelity Brokerage Services, with an aggregate market value of 11,275.17.

How many Fate Therapeutics (FATE) shares are planned to be sold under this Form 144?

The notice covers the proposed sale of 10,589 shares of Fate Therapeutics common stock.

How were the Fate Therapeutics shares being sold acquired?

The 10,589 Fate Therapeutics common shares were acquired on 01/08/2026 via restricted stock vesting from the issuer as compensation.

On which exchange will the Fate Therapeutics shares be sold?

The Form 144 states that the Fate Therapeutics common shares are expected to be sold on the NASDAQ exchange.

What is the aggregate market value of the Fate Therapeutics shares to be sold?

The aggregate market value of the 10,589 Fate Therapeutics common shares to be sold is listed as 11,275.17.

How many Fate Therapeutics shares were outstanding at the time referenced in the Form 144?

The filing notes that 115,352,289 shares of Fate Therapeutics common stock were outstanding at the time referenced.